[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphohistiocytosis-hemophagocytic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphohistiocytosis-hemophagocytic":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100542154","hemophagocytic-lymphohistiocytosis-hlh-evaluation-and-research-of-clinical-immunologic-and-transcriptome-study-100542154",false,"NCT06339177","Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study","* INCLUSION CRITERIA:\n* Aged 18 years or older.\n* Established diagnosis of sHLH defined by meeting any published criteria, per Table 1:\n\n  * Meeting the HLH-2004 criteria.\n  * HScore of \\>168. For those without a bone marrow biopsy to evaluate for hemophagocytosis (worth 35 points in the criteria), HScore\\>134 will be used.\n  * For those with underlying rheumatologic disease: meeting the 2016 American College of Rheumatology criteria for macrophage activation syndrome.\n* Agree to storage and sharing of study data and biospecimens for future research use.\n\nTable 1: Published Criteria for HLH\n\nHLH-2004 Criteria:\n\nMolecular diagnosis of HLH OR At least 5 of 8 below criteria:\n\n* Fever (\\>38.4 Degrees Celcius)\n* Splenomegaly\n* Cytopenias affecting \\>=2 of 3 lineages: Hgb \\\u003C9 g\u002FdL, platelets \\\u003C10\\^5\u002Fmicroliter, neutrophils \\\u003C10\\^6\u002Fmicroliter\n* Hypertriglyceridemia (\\>256 mg\u002FdL) and\u002For fibrinogen \\\u003C1.5 g\u002FL\n* Hemophagocytosis on biopsy\n* Serum ferritin \\>=500 ng\u002FmL\n* Increased serum sCD25 (\\>2400 U\u002FmL)\n* Low or absent NK cell activity\n\nHScore:\n\nKnown immunosuppression:\n\n0 (no) or 18 (yes)\n\nTemperature (degrees, Celsius):\n\n0 (\\\u003C38.4), 33 (38.4-39.4), 49 (\\>39.4)\n\nOrganomegaly:\n\n0 (no), 23 (liver\u002Fspleen), 38 (both)\n\nNumber of cytopenias:\n\n0 (1 lines), 24 (2 lines), 34 (3 lines)\n\nFerritin (ng\u002FmL):\n\n0 (\\\u003C2000), 35 (2000-6000), 50 (\\>6000)\n\nTriglycerides (mg\u002FdL):\n\n0 (\\\u003C1.5), 44 (1.5-4), 66 (\\>4)\n\nFibrinogen (g\u002FL):\n\n0 (\\>2.5), 30 (\\\u003C2.5)\n\nAST (IU\u002FmL):\n\n0 (\\\u003C30), 19 (\\>30)\n\nHemophagocytosis:\n\n0 (no) or 35 (yes)\n\nCutoff value=169\n\nACR 2016-MAS Criteria:\n\nA febrile patient with known or suspected sJIA is classified as having macrophage activation syndrome if the following criteria are met:\n\nFerritin \\>684 ng\u002FmL\n\nAND any 2 of the following:\n\n* Platelets \\\u003C=181,000\u002Fmicroliter\n* AST \\>48 IU\u002FmL\n* Triglycerides \\>156 mg\u002FdL\n* Fibrinogen \\\u003C=3.6 g\u002FL\n\nAbbreviations: ACR, American College of Rheumatology; AST, aspartate transaminase; Hgb, hemoglobin; HLH, hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; NK, natural killer, sJIA, systemic juvenile idiopathic arthritis.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Currently pregnant.\n* Any condition that, in the judgment of the investigator, may put the participant at undue risk or make them unsuitable for participation in the study.","ALL","18 Years","120 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","Background:\n\nHemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a nongenetic form (sHLH). They also do not have good ways to diagnose and treat sHLH.\n\nObjective:\n\nTo learn about sHLH and why some people get it and others do not.\n\nEligibility:\n\nAdults aged 18 years and older with sHLH.\n\nDesign:\n\nParticipants will be admitted to the study based on a review of their medical records. Those who join will have at least 3 clinical evaluations over 9 to 12 months. These may occur during an inpatient hospitalization if they require medical care or in the outpatient clinic.\n\nParticipants will also have a physical exam at each visit. Up to half a cup of blood will be drawn at each visit. Participants may also have their blood drawn by their own doctors, who will send the samples to the researchers. Researchers may also contact these participants by telephone or video calls.\n\nThe blood will be used for clinical tests as well as research. No new treatments will be administered as part of this study; however, standard medications and treatments may be recommended.\n\nParticipants may opt to continue their visits once a year for 3 more years. Participants may also opt for an extra clinial evaluation 1 week after starting a new treatment.\n\n...",[24,25,26,27],"Lymphohistiocytosis, Hemophagocytic","Secondary Hemophagocytic Lymphohistiocytosis","Macrophage Activation Syndrome","Hyperinflammatory Syndromes",[29,30,26,31,32,33,34,35,36,37],"Hemophagocytic Lymphohistiocytosis","HLH","MAS","Cytokine Storm Syndrome","Hyperinflammatory Syndrome","Hyperinflammation","Still's Disease","Hyperferritinemia","Immune Dysregulation","RECRUITING","2026-03-19",{"date":41,"type":42},"2026-03-20","ACTUAL",{"date":44,"type":42},"2024-07-02",{"date":46,"type":20},"2031-04-01",{"name":48,"class":49},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":80},"100619032","phase-2-prospective-single-arm-clinical-trial-of-go-regimen-for-hlh-100619032","NCT07339345","Prospective Single-Arm Clinical Trial of GO Regimen for HLH.","Prospective Single-Arm Clinical Trial of Golidocitinib Monotherapy for Hemophagocytic Lymphohistiocytosis.","Inclusion Criteria:\n\n1. Researchers evaluate patients with newly diagnosed or refractory\u002Frelapsed HLH disease.\n2. Definite diagnosis of HLH: molecular diagnosis consistent with pHLH, or at least 5 of the 8 criteria in the HLH-2004 diagnostic criteria.\n3. Patients who are currently unsuitable or unable to undergo allo-HSCT.\n4. Researchers estimate that the expected survival period exceeds one month.\n5. Patients must be at least 14 years of age and no older than 70 years of age, with no gender restrictions.\n6. Before the study began, TB was ≤10 times the upper limit of normal; Cr was ≤1.5 times the normal value.\n7. Serum HIV antigen or antibody negative。\n8. HCV antibody negative, or HCV antibody positive but HCV RNA negative.\n9. .HBsAg and HBcAb are both negative. If either of the above is positive, peripheral blood hepatitis B virus DNA titer testing is required, with a titer of less than 1×10³ copies\u002Fml.\n10. Echocardiography showed LVEF ≥ 50%.\n11. Women of childbearing age must be confirmed as not pregnant by a pregnancy test and must be willing to use effective contraception during the study period and for at least 12 months after the last dose; all male participants must use contraception during the study period and for at least 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Heart function above grade II(including II) (NYHA).\n2. Pregnancy or lactating Women and reproductive-age patients who refused to use appropriate contraceptive measures during this trial.\n3. Individuals who are allergic to GO or have a severe allergic constitution.\n4. Active bleeding of the internal organs.\n5. uncontrollable infection.\n6. Severe mental illness.\n7. History of non-melanoma skin cancer.\n8. Unable to comply during the trial and\u002For follow-up phase. Participate in other clinical research at the same time.","14 Years","70 Years",{"count":60,"type":20},28,"INTERVENTIONAL",[63,64],"PHASE2","PHASE3","This study aims to investigate the efficacy and safety of Golidocitinib(GO) monotherapy in the treatment of hemophagocytic lymphohistiocytosis.",[24],[68,69],"Hemophagocytic Lymphohistocytosis","Golidocitinib","2026-01-12",{"date":72,"type":42},"2026-01-14",{"date":74,"type":42},"2025-06-27",{"date":76,"type":20},"2027-06-27",{"name":78,"class":79},"Beijing Friendship Hospital","OTHER",1]